Compare NMM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMM | NRIX |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2007 | 2020 |
| Metric | NMM | NRIX |
|---|---|---|
| Price | $69.14 | $16.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.58 |
| AVG Volume (30 Days) | 177.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $3.66 | $26.32 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $28.37 | $8.18 |
| 52 Week High | $74.21 | $22.50 |
| Indicator | NMM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 57.50 |
| Support Level | $49.57 | $14.61 |
| Resistance Level | $68.82 | $16.47 |
| Average True Range (ATR) | 2.55 | 0.93 |
| MACD | 0.31 | 0.17 |
| Stochastic Oscillator | 62.92 | 75.96 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.